Great question! When comparing diflunisal and tafamidis for wild-type ATTR cardiomyopathy (ATTRwt-CM), tafamidis is generally considered the stronger, more established option of the two.
Here's a quick breakdown:
Tafamidis
- FDA-approved specifically for ATTR cardiomyopathy (both hereditary and wild-type)
- Shown to Show Full Answer
Great question! When comparing diflunisal and tafamidis for wild-type ATTR cardiomyopathy (ATTRwt-CM), tafamidis is generally considered the stronger, more established option of the two.
Here's a quick breakdown:
Tafamidis
- FDA-approved specifically for ATTR cardiomyopathy (both hereditary and wild-type)
- Shown to improve survival, reduce hospitalizations, and improve quality of life
- Taken once daily by mouth
- Strong clinical trial data supporting its use
Diflunisal
- Not FDA-approved for ATTR — it's used "off-label"
- Works similarly by stabilizing the TTR protein, but has less robust evidence for wild-type ATTR-CM
- Can cause stomach and kidney side effects, requiring close monitoring
- Typically reserved for early-stage disease and used with caution In short, tafamidis has much stronger clinical evidence behind it and is the preferred treatment for wild-type ATTR-CM. Diflunisal may be considered in certain situations, but it comes with more risks and less supporting data.
It's always worth discussing both options with your specialist to find what's right for your specific situation.
June 23
Join
Your Privacy Choices
